SI-BONE, Inc. Files 2023 Annual Report on Form 10-K

Ticker: SIBN · Form: 10-K · Filed: 2024-02-27T00:00:00.000Z

Sentiment: neutral

Topics: 10-K, SI-BONE, Medical Devices, Annual Report, Financials

TL;DR

<b>SI-BONE, Inc. has filed its 2023 10-K report detailing its fiscal year-end performance and financial standing.</b>

AI Summary

SI-BONE, Inc. (SIBN) filed a Annual Report (10-K) with the SEC on February 27, 2024. SI-BONE, Inc. filed its 2023 Form 10-K on February 27, 2024. The filing covers the fiscal year ending December 31, 2023. The company's principal business address is 471 El Camino Real, Suite 101, Santa Clara, CA 95050. SI-BONE, Inc. is classified under SIC code 3841 for Surgical & Medical Instruments & Apparatus. The report includes financial data for the fiscal years 2023, 2022, and 2021.

Why It Matters

For investors and stakeholders tracking SI-BONE, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of SI-BONE, Inc.'s financial health, operational performance, and strategic positioning for the fiscal year 2023, crucial for investors assessing the company's trajectory. As a medical device company specializing in surgical instruments, this filing is vital for understanding regulatory compliance, market competitiveness, and future growth prospects within the healthcare sector.

Risk Assessment

Risk Level: — SI-BONE, Inc. shows moderate risk based on this filing. The company's financial performance and future outlook are subject to the inherent risks of the medical device industry, including market competition, regulatory changes, and product adoption rates, as detailed in their 10-K filing.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to assess SI-BONE, Inc.'s performance and potential risks.

Key Numbers

Key Players & Entities

FAQ

When did SI-BONE, Inc. file this 10-K?

SI-BONE, Inc. filed this Annual Report (10-K) with the SEC on February 27, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by SI-BONE, Inc. (SIBN).

Where can I read the original 10-K filing from SI-BONE, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by SI-BONE, Inc..

What are the key takeaways from SI-BONE, Inc.'s 10-K?

SI-BONE, Inc. filed this 10-K on February 27, 2024. Key takeaways: SI-BONE, Inc. filed its 2023 Form 10-K on February 27, 2024.. The filing covers the fiscal year ending December 31, 2023.. The company's principal business address is 471 El Camino Real, Suite 101, Santa Clara, CA 95050..

Is SI-BONE, Inc. a risky investment based on this filing?

Based on this 10-K, SI-BONE, Inc. presents a moderate-risk profile. The company's financial performance and future outlook are subject to the inherent risks of the medical device industry, including market competition, regulatory changes, and product adoption rates, as detailed in their 10-K filing.

What should investors do after reading SI-BONE, Inc.'s 10-K?

Investors should review the detailed financial statements and risk factors in the 10-K to assess SI-BONE, Inc.'s performance and potential risks. The overall sentiment from this filing is neutral.

Risk Factors

Key Dates

Filing Stats: 4,506 words · 18 min read · ~15 pages · Grade level 19.2 · Accepted 2024-02-27 16:03:40

Key Financial Figures

Filing Documents

Business

Business 5 Item 1A

Risk Factors

Risk Factors 24 Item 1B Unresolved Staff Comments 58 Item 1C Cybersecurity 5 7 Item 2

Properties

Properties 59 Item 3

Legal Proceedings

Legal Proceedings 60 Item 4 Mine Safety Disclosures 60 PART II Item 5 Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 61 Item 6 [Reserved] 61 Item 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 62 Item 7A

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 73 Item 8

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 74 Item 9 Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 102 Item 9A

Controls and Procedures

Controls and Procedures 102 Item 9B Other Information 103 Item 9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 103 PART III Item 10 Directors, Executive Officers and Corporate Governance 103 Item 11

Executive Compensation

Executive Compensation 103 Item 12

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 103 Item 13 Certain Relationships and Related Transactions and Director Independence 104 Item 14 Principal Accountant Fees and Services 104 PART IV Item 15 Exhibits and Financial Statement Schedules 105 Item 16 Form 10-K Summary 107

SIGNATURES

SIGNATURES 108 1 In this Annual Report on Form 10-K, "we," "our," "us," "SI-BONE," and "the Company" refer to SI-BONE, Inc. and its consolidated subsidiaries. The SI-BONE logo and other trade names, trademarks or service marks of SI-BONE are the property of SI-BONE, Inc. This report contains references to our trademarks and to trademarks belonging to other entities. Trade names, trademarks and service marks of other companies appearing in this report are the property of their respective holders. We do not intend our use or display of other companies' trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. RISK FACTOR SUMMARY Investing in our securities involves a high degree of risk. Below is a summary of material factors that make an investment in our securities speculative or risky. Importantly, this summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, as well as other risks that we face, can be found under the heading "Item 1A. Risk Factors" below. We have incurred significant operating losses since inception, we expect to continue to incur operating losses in the future, and we may not be able to achieve or sustain future profitability; Prolonged inflation and supply chain disruptions could result in delayed product launches, lost revenue, higher costs and decreased profit margins; Disruptions in the supply of the materials and components used in manufacturing our products or the sterilization of our products by third-party suppliers could adversely affect our business, financial condition and results of operations; If hospitals, physicians, and other healthcare providers are unable to obtain and maintain adequate or any coverage and reimbursement from third-party payors for procedures performed using our products, further adoption of our products may be delayed, and it is unlikely that they will gain further acc

Business

Item 1. Business. Overview We are a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy. Leveraging our knowledge of pelvic anatomy and biomechanics, we have pioneered proprietary minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. Our products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. Since launching our first generation iFuse in 2009, we have launched new titanium implant product lines, iFuse-3D in 2017, iFuse-TORQ in 2021 and iFuse Bedrock Granite in 2022. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. We market our products primarily with a direct sales force as well as a number of third-party sales agents in the United States, and with a combination of a direct sales force, and sales agents and resellers in other countries. As of December 31, 2023, more than 95,000 procedures have been performed using our products by over 3,600 physicians in the United States and 38 other countries since we introduced iFuse in 2009. In May 2023, we received a total of $83.7 million of net proceeds from the offering of 3,775,000 shares of our common stock, and the exercise of the underwriter's option to purchase an additional 566,250 shares of our common stock, at a public offering price of $22.00 per share. Of these shares, 272,753 shares were offered by a selling stockholder, and we did not receive any proceeds from the sale by the selling stockholder. Product and Applications Our first-generation iFuse, a machined triangular titanium implant launched in 2009, has a triangular cross section that resists twisting or rotation of the implant. The triangular shape of this

View on Read The Filing